

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



杭州啓明醫療器械股份有限公司
Venus Medtech (Hangzhou) Inc.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2500)

**CHANGE OF JOINT COMPANY SECRETARY
AND AUTHORIZED REPRESENTATIVES**

The board (the “**Board**”) of directors (the “**Directors**”) of Venus Medtech (Hangzhou) Inc. (the “**Company**”) announces that Ms. Po Yi Fok (“**Ms. Fok**”) has tendered her resignation as (i) the joint company secretary of the Company (the “**Joint Company Secretary**”); (ii) an authorized representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); and (iii) an authorized representative of the Company for the acceptance of service of process and notices in Hong Kong as required under Rule 19.05(2) of the Listing Rules and under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (collectively, the “**Authorized Representatives**”) with effect from January 18, 2021.

Ms. Fok confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

Reference is made to the prospectus of the Company dated November 28, 2019 regarding the appointment of Mr. Haiyue Ma (“**Mr. Ma**”) as one of the Joint Company Secretaries and the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules in relation to the eligibility of Mr. Ma to act as the Joint Company Secretary for a period of three years from the date of the Company’s listing (i.e. December 10, 2019) to December 9, 2022 (the “**Waiver Period**”), on the condition that Ms. Fok, who meets the requirements under Rules 3.28 and 8.17 of the Listing Rules, is engaged as the Joint Company Secretary and provides assistance to Mr. Ma to acquire the “relevant experience” within the meaning of Rule 3.28 of the Listing Rules and to discharge his duties as the Joint Company Secretary during the Waiver Period. The Waiver will be revoked immediately if Ms. Fok ceases to provide assistance to Mr. Ma.

In view of Ms. Fok's resignation and since Mr. Ma does not possess the qualifications of company secretary as required under Rule 3.28 of the Listing Rules, the Company has applied for, and the Stock Exchange has granted, a new waiver from strict compliance with Rules 3.28 and 8.17 of the Listing Rules (the "**New Waiver**") for a period from the date of appointment of Mr. Wong Wai Chiu Wong ("**Mr. Wong**") to December 9, 2022 (the "**New Waiver Period**") on the conditions that (i) Mr. Ma will be assisted by Mr. Wong during the New Waiver Period and the New Waiver will be revoked immediately if and when Mr. Wong ceases to provide assistance to Mr. Ma; (ii) the Company shall notify the Stock Exchange at the end of the New Waiver Period for the Stock Exchange to re-visit the situation. The Stock Exchange expects that after the end of the New Waiver Period, the Company will be able to demonstrate that Mr. Ma can satisfy Rule 3.28 of the Listing Rules after having the benefit of Mr. Wong's assistance such that a further waiver will not be necessary; and (iii) the Company will disclose details of the New Waiver, including the reasons for and the conditions of the New Waiver. The Board is pleased to further announce that Mr. Wong has been appointed as the Joint Company Secretary and the Authorized Representatives with effect from January 18, 2021.

The biographical details of Mr. Wong are set out as follows:

Mr. Wong Wai Chiu is the associate director of SWCS Corporate Services Group (Hong Kong) Limited. Mr. Wong has over 30 years of professional services and senior management experience including acting as the chief financial officer, company secretary, information technology director and law enforcement officer in the areas of finance, accounting, regulatory compliance and enforcement, internal control, corporate governance, company secretarial work, trust and forensics accounting in multi-national banking, insurance, securities and information technology corporations and listed companies in Hong Kong as well as government departments and the Stock Exchange.

Mr. Wong is a fellow of The Hong Kong Institute of Chartered Secretaries, a fellow of the Chartered Governance Institute, a member of CPA Australia, a member of the Hong Kong Trustee Association and a certified trust practitioner.

Mr. Wong possesses a Bachelor of Social Sciences with honours in Accounting from the University of Hong Kong and various master degrees and diploma in law, alternate dispute resolution, corporate governance and information technology from renowned universities of U.K., Australia and Hong Kong.

The Board would like to take this opportunity to express its gratitude to Ms. Fok for her valuable contribution to the Company during her tenure of service, and to welcome Mr. Wong on his new appointment.

By order of the Board
Venus Medtech (Hangzhou) Inc.
Min Frank Zeng
Chairman

Hong Kong, January 18, 2021

As at the date of this announcement, the executive Directors are Mr. Min Frank Zeng, Mr. Zhenjun Zi and Mr. Lim Hou-Sen (Lin Haosheng); the non-executive Director is Ms. Nisa Bernice Wing-Yu Leung; and the independent non-executive Directors are Mr. Ting Yuk Anthony Wu, Mr. Wan Yee Joseph Lau and Mr. Chi Wai Suen.